## ⚠ Content Warning

This report covers topics classified as sensitive (health). Information is aggregated from public sources for informational purposes only. This is not medical advice. Consult a qualified professional before acting on any information here.

---
last_verified: "2026-05-20T01:25:04.378Z"
---
schema_type: "SoftwareApplication"
entity_type: "Mobile Application"
app_name: "Johns Hopkins Antibiotic Guide"
developer_entity: "Unbound Medicine, Inc."
bundle_id: "com.unboundmedicine.JohnsHopkinsPOCITGuides"
app_store_id: "429504851"
google_play_id: "com.unbound.android.ubjhl"
category: "Medical"
primary_platform: "ios"
primary_monetization: "Subscription"
offline_capable: false
market_region: "US"
platforms: "iOS & Android"
app_last_updated: "2026-04-06"
report_date: "2026-05-20"
last_verified: "2026-05-20"
report_version: "1.40"
total_reviews: 5025
overall_rating: 4.85
sentiment: "Mixed"
sentiment_score: 45
confidence: "medium"
confidence_score: 0.8
top_praise_theme: "Comprehensive antibiotic reference content provides essential clinical support for hospitalists and infectious disease specialists"
top_complaint_theme: "Restrictive device management policies block access for users switching between multiple mobile phones"
top_request_theme: "Flexible multi-device access to allow clinicians to use the guide across different hardware"
review_sample_size: 100
total_review_count: 100
analyzed_review_count: 60
data_age_days: 0
momentum_velocity: "maintenance"
intelligence_version: 3
nemesis: "AMBOSS Medical Knowledge"
competitor_count: 8
tags: ["medical", "subscription", "mixed sentiment", "mobile app", "app review", "app analysis", "clinicians", "medical", "professionals"]
canonical_url: "https://marlvel.ai/intel-report/medical/com-unboundmedicine-johnshopkinspocitguides"
license: "CC-BY-NC 4.0"
content_version: "v2"
---

# Johns Hopkins Antibiotic Guide App Audit

## TL;DR {#tldr}

- **Category**: Medical · Subscription
- **Signal**: Rating 4.85 · Sentiment Mixed
- **Recent focus**: Restrictive device management policies block access for users switching between multiple mobile phones (top complaint) · Comprehensive antibiotic reference content provides essential clinical support for hospitalists and infectious disease specialists (top praise) · Flexible multi-device access to allow clinicians to use the guide across different hardware (top request)

> **TL;DR:** Johns Hopkins Antibiotic Guide is a medical app by Unbound Medicine, Inc., rated 4.85/5 by 5K users, with Mixed user sentiment (45/100), available on iOS & Android.
>
> **Marlvel.ai App Intelligence** — Independent analysis. US Market. No publisher influence.

<!-- speakable-start -->
> **Key Insight:** Johns Hopkins Antibiotic Guide shows Mixed sentiment (4.85/5 from 5K reviews) — users praise comprehensive antibiotic reference content provides essential clinical support for hospitalists and infectious disease specialists but report issues with restrictive device management policies block access for users switching between multiple mobile phones.
<!-- speakable-end -->

## Quick Facts

| Fact | Value |
| :--- | :--- |
| **Rating** | 4.85/5 (5K reviews) |
| **User Mood** | Mixed |
| **Category** | Medical |
| **Developer** | Unbound Medicine, Inc. |
| **Pricing** | Subscription |
| **Platforms** | iOS & Android |
| **Confidence** | Medium (0.8/1.0) |
| **Data Age** | 0d |

## Metadata & Market Performance
- **Publisher:** Unbound Medicine, Inc.
- **Category:** Medical
- **Target Audience:** Clinicians and medical professionals requiring evidence-based, frequently updated decision support at the point of care.
- **Platforms:** iOS & Android
- **Version Audited:** 1.40
- **Audit Date:** 2026-05-20
- **Signal Count:** 100 reviews analyzed
- **Confidence:** Medium (0.8/1.0)
- **App Store ID (iOS):** 429504851
- **Bundle ID:** com.unboundmedicine.JohnsHopkinsPOCITGuides
- **Google Play ID:** com.unbound.android.ubjhl
- **Performance Trend:** Declining
- **Data Window:** Analysis based on signals collected up to 2026-05-20
- **Short Description:** Try for 14 days — Hopkins Antimicrobial Therapy, HIV, Diabetes, Psych Guidelines

<!-- section:executive-snapshot -->
## Executive Snapshot
**What it is:** Johns Hopkins Antibiotic Guide is a clinical reference app for medical professionals, providing evidence-based antimicrobial, HIV, diabetes, and psychiatry guidelines on iOS and Android.
**Why users hire it:** Clinicians hire this app to access verified, expert-curated medical data at the point of care, reducing the risk of diagnostic or dosing errors during hospital shifts.
<!-- /section:executive-snapshot -->

<!-- section:features -->
## App DNA (Features & Intent)
- **[Differentiator] Evidence-based Clinical Guides:** Curated antimicrobial, HIV, diabetes, and psychiatry clinical references updated monthly by Johns Hopkins experts
  * *User Intent:* Users need clear guidance to understand and adopt the product quickly.
- **[Differentiator] Psychedelic Medicine Guidance:** Clinical application, safety, and ethical protocols for psychedelic medicine added to the psychiatry module
  * *User Intent:* Users seek enhanced value through premium features.
- **[Standard] Point-of-Care Search:** Enhanced search functionality for rapid access to drug interactions, dosing, and differential diagnoses
  * *User Intent:* Users want to quickly find relevant content or features.
<!-- /section:features -->

## Monetization Strategy
- **Model:** Subscription
- **Tiers:** Free 14-day trial, $29.99/year per guide, $79.99/year for 4-guide bundle
- **Analysis:** Subscription model anchored at $29.99 per guide, with a bundle discount to drive higher average revenue per user.

<!-- section:sentiment -->
## 🟡 User Sentiment (Medium Confidence: 60 of 100 reviews analyzed) {#user-sentiment}
- **Overall Rating:** 4.85/5
- **Platform Split:** iOS 4.9/5 (3.7K ratings) | Android 4.8/5 (1.3K ratings)
- **Overall Sentiment:** Mixed

### Top Praises
- **Comprehensive antibiotic reference content provides essential clinical support for hospitalists and infectious disease specialists**

### Top Complaints (Impact Areas)
- **Restrictive device management policies block access for users switching between multiple mobile phones**

### Top Requests (What Users Want)
- **Flexible multi-device access to allow clinicians to use the guide across different hardware**

<!-- /section:sentiment -->
<!-- section:swot -->
## SWOT Analysis {#swot}

**Core Strengths:**
- Brand authority of Johns Hopkins content sustains high-trust clinical adoption
- Monthly content update cadence maintains relevance in fast-moving infectious disease fields
- Point-of-care search utility minimizes cognitive load for hospitalists

**Critical Frictions:**
- Restrictive device-locking policies drive high churn among multi-device users
- Opaque subscription billing processes trigger negative sentiment
- Technical instability in purchase restoration flows blocks access to paid content

**Growth Levers:**
- Expansion into wearable-integrated clinical alerts
- B2B partnerships with hospital systems for enterprise-wide access
- AI-driven natural language query integration to compete with OpenEvidence

**Market Threats:**
- AMBOSS's integrated educational ecosystem siphons professional attention
- OpenEvidence's AI synthesis reduces the value of manual editorial curation
- High-velocity digital health platforms shift user expectations toward active intervention

<!-- /section:swot -->
## Recent Changes (v2 → v3) {#recent-changes}

The app's competitive position is declining due to restrictive device-locking policies and a reduced trial period, despite maintaining high-quality clinical content.

**Overall trend**: Declining
**Compared at**: 2026-05-20

### High-impact changes
- **[Declined] Sentiment Score and Overall Rating** (sentiment) — Sentiment score dropped from 62 to 45, shifting the overall sentiment classification from positive to mixed.
- **[Added] Device-Locking Complaints** (sentiment) — New user complaint theme emerged regarding restrictive device management policies that prevent access when switching hardware.
- **[Shifted] Trial Duration Reduction** (pricing) — Free trial period decreased from 30 days to 14 days.

### Medium-impact changes
- **[Added] Competitive Threats** (swot) — SWOT analysis now includes specific threats from AMBOSS and OpenEvidence, which were not previously listed.
- **[Shifted] Development Focus** (positioning) — Development cadence shifted to maintenance-only, focusing exclusively on payment infrastructure rather than content or feature growth.

<!-- section:rivals -->
## Rivals Landscape {#rivals}

> Competitive positioning identified by AI analysis of app features, category, and market signals.

### Johns Hopkins Antibiotic Guide vs AMBOSS Medical Knowledge — Head to Head
- **[AMBOSS Medical Knowledge](https://marlvel.ai/intel-report/medical/us-miamed-amboss-knowledge)** by AMBOSS: AMBOSS serves the exact same professional medical audience with a comprehensive, evidence-based knowledge platform that directly competes with the Johns Hopkins Guide's clinical decision support utility.
  - **Moat strength:** High — sustainable advantage over 12 months
  - **Key differences:**
    - Integrates interactive Q&A and study modes that drive daily engagement beyond simple reference lookups.
    - Provides a unified cross-platform experience that bridges clinical practice with medical education and board preparation.
    - Maintains a high-velocity content update cycle that keeps clinical guidelines current with emerging medical literature.
  - **Where Johns Hopkins Antibiotic Guide wins:**
    - ✅ Focuses exclusively on high-trust, curated Johns Hopkins content which provides a specific brand-authority advantage.
    - ✅ Offers a streamlined, reference-first interface that minimizes cognitive load for clinicians needing rapid answers.
  - **Where AMBOSS Medical Knowledge wins:**
    - ❌ Leverages a broader ecosystem of medical knowledge that supports the entire lifecycle of a medical professional.
    - ❌ Utilizes advanced search and cross-referencing capabilities that allow users to navigate complex clinical topics faster.
  - **Verdict:** The target app must leverage its specific Johns Hopkins brand authority to defend against AMBOSS's superior platform breadth and integrated educational features.

### Contenders (Strong Challengers)
- **[Doximity](https://marlvel.ai/intel-report/medical/com-doximity-directoryv10)** by Doximity [Moat: High]: Doximity acts as a massive professional network for clinicians, creating a high-frequency utility that captures the same target audience's attention.
  - Provides a secure, HIPAA-compliant communication layer that integrates directly into the clinician's daily workflow.
  - Offers a massive professional directory and news feed that creates a network effect the target app lacks.
- **[OpenEvidence](https://marlvel.ai/intel-report/medical/com-openevidence)** by OpenEvidence Inc. [Moat: Medium]: OpenEvidence uses AI to synthesize medical literature, directly challenging the target app's value proposition of providing expert-curated clinical recommendations.
  - Utilizes generative AI to provide instant, evidence-based answers to complex clinical queries in real-time.
  - Aggregates and summarizes vast amounts of peer-reviewed literature faster than traditional manual editorial processes.
- **[Vargo Anesthesia Mega App](https://marlvel.ai/intel-report/medical/com-insertnamehere-vargomasterapp)** by Vargo Anesthesia Inc [Moat: Medium]: Vargo serves a specialized clinical niche with high-utility reference tools, representing a direct threat to the target app's specialized clinical guide market.
  - Delivers highly specialized, procedure-specific anesthesia calculators and drug dosing tools for high-stakes clinical environments.
  - Maintains a deep, narrow focus on anesthesia-specific workflows that provides superior utility for that specific demographic.

### Peers (What They Do Better)
- **[athenaPatient](https://marlvel.ai/intel-report/medical/com-athenahealth-athenapatient)** by athenahealth: While patient-facing, it occupies the same medical ecosystem and competes for the clinician's attention via EHR integration.
  - Connects directly to the EHR to facilitate patient-provider communication and administrative workflow management.
  - Focuses on the patient-side experience of clinical care rather than the provider's reference-based decision support.
- **[Migraine Buddy: Track Headache](https://marlvel.ai/intel-report/medical/com-healint-migrainebuddy)** by Voluntis: Represents a specialized clinical tracking tool that competes for the same medical category space.
  - Provides longitudinal data tracking for specific chronic conditions, offering insights that static guides cannot.
  - Engages users through community-driven support and symptom logging rather than clinical reference material.

### New Kids on the Block (What's Innovative)
- **[Sword Health: AI Care](https://marlvel.ai/intel-report/medical/com-swordhealth-guarda-ios)** by Sword Health, Inc: Demonstrates high release velocity and an innovative AI-first approach to clinical care delivery.
- **[Kaia Health](https://marlvel.ai/intel-report/medical/com-kaia-health-meteor)** by Kaia Health Software GmbH: Emerging as a digital health platform that leverages AI to provide clinical-grade guidance for chronic pain management.

<!-- /section:rivals -->
<!-- section:whats-new -->
## What's New

- **Latest (v2.8.52, 1 months ago):** Optimized purchase and restore flows.
<!-- /section:whats-new -->

<!-- section:momentum -->
## App Momentum (Maintenance) {#momentum}

No new feature builds or events in recent patches; the app ships minor updates focused on payment processing at a roughly 3-month cadence.

> **Cadence:** 4 total versions · 0 majors in last 6 months · 43 days since last update · 70 days avg between updates

<!-- /section:momentum -->

<!-- section:so-what -->
## The "So What?" (Strategic Takeaway) {#so-what}

Johns Hopkins Antibiotic Guide is an established medical app that is available.
With a 4.85/5 rating from 5K reviews, it shows polarized user reception.

<!-- speakable-start -->
> **Bottom Line:** The app maintains high utility as a clinical reference, but its reputation is damaged by restrictive device-locking and opaque billing, so the PM must prioritize account-syncing and billing transparency to defend the core user base.
<!-- speakable-end -->

**Best for:** Clinicians and medical professionals requiring evidence-based, frequently updated decision support at the point of care.

<!-- section:pm-actions -->
### PM Action Plan (Next Best Moves)

- [ ] [INVEST] [HIGH IMPACT] Enable multi-device account syncing because device-locking is the top churn driver → improve retention — *User reviews explicitly cite device-locking as a major frustration and churn trigger.* _(trade-off: deprioritize Push the wearable companion app sprint to Q3 — wearables waitlist is smaller than current churn volume.)_
- [ ] [PIVOT] [HIGH IMPACT] Audit subscription billing flow because opaque charges trigger high-frequency negative sentiment → reduce refund surge — *Customers report being charged without clear warning after trial periods.* _(trade-off: deprioritize Pause the price-test on the annual tier — refund surge has 4x the revenue impact.)_
<!-- /section:pm-actions -->

<!-- section:feature-gaps -->
### Feature Gaps vs Competitors

- Interactive Q&A and study modes (available in AMBOSS)
- Unified cross-platform educational ecosystem (available in AMBOSS)
- Generative AI-based clinical query synthesis (available in OpenEvidence)
<!-- /section:feature-gaps -->

<!-- section:outlook -->
### Outlook: Mixed

The clinical reference market is consolidating around platforms that offer integrated educational and AI-driven synthesis, leaving static guides like this one exposed to churn. The app's future depends on transitioning from a single-device reference tool to a multi-device, AI-augmented clinical assistant to match the utility of modern rivals.

- 🔴 Restrictive device-locking policies continue to drive negative sentiment, which compounds the churn risk among professional users who rely on multiple devices.
- 🟢 The latest update to the psychiatry guide shows active content investment, ensuring the app remains a primary reference for specialized clinical practitioners.
<!-- /section:outlook -->

<!-- /section:so-what -->

<!-- section:metrics -->
## Key Metrics Summary

| Metric | Value |
| :--- | :--- |
| Overall Rating | 4.85/5 |
| Total Reviews | 5K |
| Sentiment | Mixed (45/100) |
| Confidence | Medium |
| Pricing Model | Subscription |
| Platforms | iOS & Android |
| Key Features | 3 analyzed |
| Trend | Declining |
| Outlook | Mixed |
<!-- /section:metrics -->

## Competitor Comparison

| App | Rating | Sentiment | Developer |
| :--- | :--- | :--- | :--- |
| **Johns Hopkins Antibiotic Guide** (this app) | 4.85/5 | Mixed | Unbound Medicine, Inc. |
| [Sword Health: AI Care](https://marlvel.ai/intel-report/medical/com-swordhealth-guarda-ios) | 4.7/5 | N/A | Sword Health, Inc |
| [Doximity](https://marlvel.ai/intel-report/medical/com-doximity-directoryv10) | 4.8/5 | N/A | Doximity |
| [Vargo Anesthesia Mega App](https://marlvel.ai/intel-report/medical/com-insertnamehere-vargomasterapp) | 4.7/5 | N/A | Vargo Anesthesia Inc |
| [OpenEvidence](https://marlvel.ai/intel-report/medical/com-openevidence) | 4.9/5 | N/A | OpenEvidence Inc. |
| [Migraine Buddy: Track Headache](https://marlvel.ai/intel-report/medical/com-healint-migrainebuddy) | 4.8/5 | N/A | Voluntis |

## Company Profile
- **Developer:** Unbound Medicine, Inc.
- **Website:** [https://www.hopkinsguides.com/](https://www.hopkinsguides.com/)
- **Social:** [Instagram](https://www.instagram.com/unboundmedicine) · [Facebook](https://www.facebook.com/unboundmedicineinc) · [YouTube](https://www.youtube.com/unboundmedicine) · [LinkedIn](https://www.linkedin.com/company/unbound-medicine)

## Data Sources & Links
- **App Store:** [View on Apple Store](https://apps.apple.com/us/app/johns-hopkins-antibiotic-guide/id429504851?uo=2)
- **Google Play:** [View on Google Play](https://play.google.com/store/apps/details?id=com.unbound.android.ubjhl&hl=en&gl=us)
- **Dev Site:** [Official Website](https://www.hopkinsguides.com/)
- **Sources:** Developer website content, App store metadata, User reviews.

## Related Intel Reports
- [*Sword Health: AI Care*](https://marlvel.ai/intel-report/medical/com-swordhealth-guarda-ios) (Sword Health, Inc) — 4.7/5 Rating | N/A Sentiment
- [*Doximity*](https://marlvel.ai/intel-report/medical/com-doximity-directoryv10) (Doximity) — 4.8/5 Rating | N/A Sentiment
- [*Vargo Anesthesia Mega App*](https://marlvel.ai/intel-report/medical/com-insertnamehere-vargomasterapp) (Vargo Anesthesia Inc) — 4.7/5 Rating | N/A Sentiment
- [*OpenEvidence*](https://marlvel.ai/intel-report/medical/com-openevidence) (OpenEvidence Inc.) — 4.9/5 Rating | N/A Sentiment
- [*Migraine Buddy: Track Headache*](https://marlvel.ai/intel-report/medical/com-healint-migrainebuddy) (Voluntis) — 4.8/5 Rating | N/A Sentiment
- [*Kaia Health*](https://marlvel.ai/intel-report/medical/com-kaia-health-meteor) (Kaia Health Software GmbH) — 4.8/5 Rating | N/A Sentiment
- [*AMBOSS Medical Knowledge*](https://marlvel.ai/intel-report/medical/us-miamed-amboss-knowledge) (AMBOSS) — 4.9/5 Rating | Excellent Sentiment
- [*athenaPatient*](https://marlvel.ai/intel-report/medical/com-athenahealth-athenapatient) (athenahealth) — 4.9/5 Rating | N/A Sentiment
- [*Move On with AJ*](https://marlvel.ai/intel-report/medical/move-on-with-aj) (Universal Relaxation Ltd) — 4.3/5 Rating | Positive Sentiment
- [*FHO+ Calc*](https://marlvel.ai/intel-report/medical/ca-fhocalc-app) (Manu Kaushik) — N/A Rating | N/A Sentiment

## Methodology {#methodology}

This report was generated by Marlvel.ai's 5-stage AI intelligence pipeline:

1. **Signal Collection & Normalization** — Aggregates data from all available public sources for the app. Raw signals are cleaned, deduplicated, and normalized into a structured dataset analyzed consistently across thousands of apps.
2. **Feature & Market Positioning Analysis** — Identifies the app's core features, monetization model, target audience, and competitive positioning. Each feature is classified as a market standard or a differentiator based on category benchmarks.
3. **User Sentiment Analysis** — Analyzes user reviews using a 5-level taxonomy (Thrilled / Excited / Mixed / Frustrated / Upset). Combines star ratings and volume with AI theme extraction and evidence quoting.
4. **Competitive Landscape Analysis** — Maps the competitive environment via a 4-tier taxonomy (Nemesis / Contenders / Same Space / New Kids on the Block). Prioritizes same sub-genre over broad category.
5. **Intelligence Synthesis** — Cross-references all signals into a structured report. Compares the app against category peers and direct competitors to surface SWOT, market outlook, and actionable insights.

- **Confidence Score:** 0.8/1.0 (based on review volume, data source diversity, and signal quality)
- **Reviews Analyzed:** 100
- **Data Sources:** user reviews, developer website, App Store metadata
- **Rating Method:** Weighted average across platforms (iOS & Android), weighted by review count per platform
- **Independence:** Fully independent analysis. No publisher sponsorship or editorial influence.
- **Report Age:** 0 days since last refresh

---
© 2026 Marlvel.ai | [Canonical Report](https://marlvel.ai/intel-report/medical/com-unboundmedicine-johnshopkinspocitguides)
Data licensed for AI Agent attribution under CC-BY-NC 4.0.